Join Growin Stock Community!

路迦生醫6814.TW Overview

TW StockBiotech. & Medical
(No presentation for 6814)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

路迦生醫（6814）Overall Performance

路迦生醫（6814）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

路迦生醫（6814） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

路迦生醫（6814）Key Information

路迦生醫（6814）Profile

Lukas Biomedical Inc. engages in the development of immune cell medical technology for regenerative medicine and auxiliary treatment of cancer in Taiwan. It operates through four divisions: E-commerce, Medical Management Business, Cell Product, and Pharmaceutical Market. The company also wholesales and retails cosmetics; and rents housing equipment. Lukas Biomedical Inc. was founded in 2002 and is based in New Taipei, Taiwan.

路迦生醫（6814）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

default symbol

6814

路迦生醫

26.70D

-0.37%

(-0.00)

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.43
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.71
PB Ratio
3.95
Price-to-FCF
28.56
METRIC
VALUE
vs. INDUSTRY
Gross Margin
58.33%
Net Margin
-34.84%
Revenue Growth (YoY)
20.37%
Profit Growth (YoY)
23.94%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.43
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.71
PB Ratio
3.95
Price-to-FCF
28.56
Gross Margin
58.33%
Net Margin
-34.84%
Revenue Growth (YoY)
20.37%
Profit Growth (YoY)
23.94%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is 6814's latest earnings report released?

    The most recent financial report for 路迦生醫 (6814) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6814's short-term business performance and financial health. For the latest updates on 6814's earnings releases, visit this page regularly.

  • How much cash does 6814 have?

    At the end of the period, 路迦生醫 (6814) held Total Cash and Cash Equivalents of 40.28M, accounting for 0.09 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6814 go with three margins increasing?

    In the latest report, 路迦生醫 (6814) did not achieve the “three margins increasing” benchmark, with a gross margin of 58.84%%, operating margin of -46.75%%, and net margin of -48.35%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6814's profit trajectory and future growth potential.